The CoVIg-19 Plasma Alliance was established
On May 8, 2020, the CoVIg-19 Plasma Alliance was announced, an unprecedented partnership of the world’s leading plasma…
AbbVie completed acquisition of Allergan for nearly $62 billion
On May 8, 2020, AbbVie announced it had completed its acquisition of Allergan following receipt of regulatory approval…
Biotechnology | COVID-19 | Life Science News | Nanotechnology | Pharmaceutical | Therapeutics | Vaccine
Entos Pharma partnered with Precision NanoSystems to enable scalable GMP manufacturing of Fusogenix DNA COVID-19 vaccine
On May 7, 2020, Entos Pharmaceuticals announced a partnership with PrecisionNanoSystems (PNI) to produce clinica lgrade vaccines and…
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On May 6, 2020, Mesoblast announced that the first patients were dosed in the 300-patient randomized placebo-controlled Phase…
Biotechnology | COVID-19 | Diagnostics | Life Science News | Medical Device | Non-Profit Research | Pharmaceutical | Therapeutics
USPTO launched platform to facilitate connections between patent holders and potential licensees in key technologies
On May 4, 2020, the U.S. Patent and Trademark Office (USPTO) unveiled a new web-based intellectual property marketplace…
Mesoblast began enrollment in phase 2/3 clinical trial of remestemcel-L in 300 patients with acute respiratory distress syndrome
On Apr. 30, 2020, Mesoblast announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic…
Entos Pharmaceuticals partnered with EpiVax to develop a pan-Coronavirus DNA vaccine
On Apr. 28, 2020, Entos Pharmaceuticals announced a collaboration with EpiVax. This partnership combined the Entos Fusogenix DNA…
Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
On Apr. 27, 2020, Regeneron and Sanofi announced the primary endpoint of overall survival was met in a…
Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome
On Apr. 24, 2020, Mesoblast announced an 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory…
Emergent BioSolutions signed agreement to be U.S. manufacturing partner for Johnson & Johnson’s lead vaccine candidate for COVID-19
On Apr. 23, 2020, Emergent BioSolutions announced an agreement whereby Emergent will deploy its contract development and manufacturing…
Cocrystal Pharma expanded exclusive license agreement with Kansas State University Research Foundation to new Coronavirus antiviral compound
On Apr. 22, 2020, Cocrystal Pharma announced it has expanded its previously announced license agreement with Kansas State…
ViralClear submited application for Vicromax through FDAs Coronavirus Treatment Acceleration Program for accelerated clinical trials
On Apr. 21, 2020, BioSig Technologies announced that subsidiary ViralClear Pharmaceuticals, had submitted an application for Vicromax(tm) (merimepodib,…
Chugai started phase III clinical trial of Actemra for COVID-19 pneumonia in Japan
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
Teva donated potential COVID-19 treatment, hydroxychloroquine sulfate tablets to hospitals nationwide
On Mar. 19, 2020, Teva announced the immediate donation of more than 6 million doses of hydroxychloroquine sulfate…
Innovation Pharmaceuticals Brilacidin tested as drug and vaccine at different institutions
On Mar. 17, 2020, Innovation Pharma announced details on the Material Transfer Agreement signed with a leading public…
Enanta Pharmaceuticals announced efforts to discover treatment for novel Coronavirus disease
On Mar. 13, 2020, Enanta Pharmaceuticals announced it had initiated a program to discover direct-acting antiviral drug candidates…
Cocrystal Pharma announced plans to advance Coronavirus program
On Mar. 6, 2020, Cocrystal Pharma announced it had initiated its Coronavirus program. Cocrystal previously entered into a…
FDA approved Lundbeck’s VYEPTI™ – the first and only intravenous preventive treatment for migraine
On Feb. 21, 2020, Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) had been approved by the U.S. Food and Drug…
Sanofi joined with US Dept of Health and Human Services to advance novel coronavirus vaccine
On Feb. 18, 2020, Sanofi announced it had leveraged previous development work for a SARS vaccine which may…
BioMotiv and Bristol-Myers Squibb announced the Launch of Anteros Pharmaceuticals
On Feb. 4, 2020, BioMotiv and Bristol-Myers Squibb announced the launch of Anteros Pharmaceuticals, a biotechnology company focused…
Alexion completed acquisition of Achillion for $930 million
On Jan. 28, 2020, Alexion Pharma announced it had completed its acquisition of Achillion Pharmaceuticals for $930 million….
Biotechnology | CDC | FDA | Life Science News | NIH | Non-Profit Research | Pharmaceutical | Vaccine
CDC published updated ACIP recommendations for use of PCV13 and PPSV23 pneumococcal vaccines for adults age 65 and older
On Nov. 22, 2019, the Centers for Disease Control and Prevention”s (CDC) Advisory Committee on Immunization Practices (ACIP)…
Merck acquired San Diego’s Calporta for up to $576 million
On Nov. 12, 2019, Calporta Therapeutics, one of eight San Diego biotech companies Avalon Ventures created with GlaxoSmithKline,…
Lundbeck acquired Alder BioPharmaceuticals for $1.95 billion
On Oct. 22, 2019, Lundbeck, located in Valby, Denmark, announced it had completed its acquisition of Bothell, Washington-based…
CPRIT granted $18.7 million New Company Product Development award to Salarius Pharmaceuticals
On Aug. 15, 2019, the Cancer Prevention and Research Institute of Texas (CPRIT) announced that it was awarded…
Chembio Diagnostics and Takeda Pharmaceutical announced collaboration to develop point-of-care diagnostic test
On Jul. 18, 2019, Chembio Diagnostics announced a collaboration with Shire Human Genetic Therapies, a wholly owned subsidiary…
FDA approved use of the 05 mL dose of Sanofi’s Fluzone Quadrivalent influenza vaccine to include children age 6 through 35 months
On Jan. 23, 2019, U.S. Food and Drug Administration (FDA) announced it had approved approved the use of…
Takeda Pharmaceutical acquired Shire
On Jan. 8, 2019, Takeda Pharmaceutical announced the completion of its acquisition of Lexington, Massachusetts-based Shire for $62…
Discovery Life Sciences expanded by merging with Conversant Bio, Folio Bio, and Phylogeny
On Oct. 16, 2018, Discovery Life Sciences expanded by merging with Conversant Bio, Folio Bio, and Phylogeny to…
Teva Pharmaceuticals announced North America headquarters moved to New Jersey
On Jul. 6, 2018, Teva Pharmaceuticals announced it would move its U.S. headquarters to Parsippany-Troy Hills, New Jersey…